Paper17469105
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO and 12 others. Arthritis Rheum, 2007. Cited by 171 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Papers, record 17469105. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17469105
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antirheumatic Agents | Major topic |
| B-Cell Activating Factor | Major topic |
| B-Lymphocytes | Major topic |
| Sjogren's Syndrome | Major topic |
| Antibodies, Monoclonal, Murine-Derived | |
| B-Lymphocyte Subsets | |
| Biopsy | |
| Dose-Response Relationship, Drug | |
| Humans | |
| Lymphocyte Depletion | |
| Rituximab | |
| Salivary Glands |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17469093 | Will targeting B cells be the answer for Sjögren's syndrome? | https://conductscience.org/library/papers/17469093 |
Source PubMed
Cited by60
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 171 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42342283 | Emerging treatments for Sjögren's disease: promising drugs on the horizon. | RMD Open | 2026 | https://conductscience.org/library/papers/42342283 | PubMed |
| 41912841 | Evaluation of Effectiveness of Long-Term Therapy with Russian Rituximab Biosimilar (Acellbia) in Sjogren's Disease in Real Clinical Practice. | Dokl Biochem Biophys | 2026 | https://conductscience.org/library/papers/41912841 | PubMed |
| 41456033 | Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report. | Thyroid Res | 2025 | https://conductscience.org/library/papers/41456033 | PubMed |
| 40646392 | The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine. | Clin Rev Allergy Immunol | 2025 | https://conductscience.org/library/papers/40646392 | PubMed |
| 39469708 | Immune and non-immune mediators in the fibrosis pathogenesis of salivary gland in Sjögren's syndrome. | Front Immunol | 2024 | https://conductscience.org/library/papers/39469708 | PubMed |
| 39209370 | Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren's disease. | RMD Open | 2024 | https://conductscience.org/library/papers/39209370 | PubMed |
| 39061958 | Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease. | Biomedicines | 2024 | https://conductscience.org/library/papers/39061958 | PubMed |
| 37751119 | B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study. | Clin Exp Med | 2023 | https://conductscience.org/library/papers/37751119 | PubMed |
| 37446355 | Outline of Salivary Gland Pathogenesis of Sjögren's Syndrome and Current Therapeutic Approaches. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37446355 | PubMed |
| 36477362 | A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome. | JCI Insight | 2022 | https://conductscience.org/library/papers/36477362 | PubMed |
| 36029718 | Dual B-cell targeting therapy ameliorates autoimmune cholangitis. | J Autoimmun | 2022 | https://conductscience.org/library/papers/36029718 | PubMed |
| 34951923 | New developments in Sjogren's syndrome. | Rheumatology (Oxford) | 2021 | https://conductscience.org/library/papers/34951923 | PubMed |
| 34788412 | Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab? | Rheumatology (Oxford) | 2022 | https://conductscience.org/library/papers/34788412 | PubMed |
| 34476406 | Short-term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection. | Kidney360 | 2020 | https://conductscience.org/library/papers/34476406 | PubMed |
| 34336905 | Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation. | Front Med (Lausanne) | 2021 | https://conductscience.org/library/papers/34336905 | PubMed |
| 32573488 | Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses. | JCI Insight | 2020 | https://conductscience.org/library/papers/32573488 | PubMed |
| 32547535 | Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. | Front Immunol | 2020 | https://conductscience.org/library/papers/32547535 | PubMed |
| 31508200 | Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren's syndrome. | F1000Res | 2019 | https://conductscience.org/library/papers/31508200 | PubMed |
| 30472652 | Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome. | Ann Rheum Dis | 2019 | https://conductscience.org/library/papers/30472652 | PubMed |
| 29416129 | B cells in the pathogenesis of primary Sjögren syndrome. | Nat Rev Rheumatol | 2018 | https://conductscience.org/library/papers/29416129 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| CD5 | 921 | PubTator's text mining | https://conductscience.org/library/genes/921 | NCBI Gene |
| TNFSF13B | 10673 | PubTator's text mining | https://conductscience.org/library/genes/10673 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17469105
GET https://conductscience.org/api/papers/v1/17469105/cited_by?page=2